Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario
Fatiregun OA, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. BMC Cancer. 2026; Mar 19 [Epub ahead of print].
Background and aims — Primary sclerosing cholangitis (PSC) is a pre-malignant condition with elevated risk of hepatopancreatobiliary cancers (HPBCa) and colorectal cancer (CRC) when inflammatory bowel disease (IBD) is present. We described cancer burden in a contemporary PSC–IBD cohort, and assessed rates of subsequent cancers, liver transplant, and death post-colectomy or post-cholecystectomy status.
Methods — Using linked health administrative databases, we calculated cause-specific cumulative incidences of HPBCa-related outcomes (diagnoses/deaths) and non-HPBCa-related transplant/death among individuals with PSC–IBD in Ontario, Canada (2002–2018), followed to 2021. Transition probabilities and transition intensity ratios (TIR) were evaluated using a multistate Markov model.
Results — Among 476 individuals with incident PSC–IBD, there was a 54% probability of remaining event-free at 10 years. Approximately 1 in 20 experienced an HPBCa-related outcome, and up to 1 in 4 had a non-HPBCa-related transplant/death. During follow-up, 13% experienced multiple events. Age was associated with HPBCa (HR 1.02, 95% CI 1.01–1.04), but not sex. Mortality occurred more frequently post-colectomy (TIR 3.08, 95% CI 1.7–5.59) and post-cholecystectomy (TIR 3.85, 95% CI 2.21–6.64) relative to event-free PSC–IBD, but there were no differences in post-surgery incidence of cancer or transplant.
Conclusions — While some individuals with PSC–IBD experienced an extended event-free disease course, a large proportion experienced disease-related cancer, colectomy, cholecystectomy, and transplant events. Higher mortality rates observed after surgery were likely related to underlying disease processes that motivated surgical intervention (eg, dysplasia/malignancy, refractory IBD), rather than the surgery itself. Understanding how PSC–IBD disease trajectories vary can inform individual management and patient counselling.
Leung KK, Li W, Hansen B, Gulamhusein A, Lapointe-Shaw L, Ricciuto A, Benchimol EI, Flemming JA, Hirschfield GM. Hepatology. 2026; Feb 4 [Epub ahead of print].
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.